Abstract
A new era of cancer immunotherapy has begun. Chimeric antigen receptor T (CAR-T) cells, with T cells genetically engineered to recognize CD-19 antigens of B cells, have been confirmed to successfully treat relapsed and refractory B cell malignancies in various clinical trials.[1][1] However, this
Highlights
CAR technology is being applied to other immune cells such as natural killer (NK) cells
Tumors can escape the cytotoxicity of NK cells when they are directed against NKG2D ligands MICA and MICB.[3]
Preclinical research has been reported for CAR-modified primary human NK cells redirected against CD19, CD20, CD244, and HER2, as well as CARexpressing NK-92 cells targeted to a wider range of cancer antigens.[4]
Summary
CAR technology is being applied to other immune cells such as natural killer (NK) cells. Tumors can escape the cytotoxicity of NK cells when they are directed against NKG2D ligands MICA and MICB (major histocompatibility complex class I chain-related protein A/B).[3] preclinical research has been reported for CAR-modified primary human NK cells redirected against CD19, CD20, CD244, and HER2, as well as CARexpressing NK-92 cells targeted to a wider range of cancer antigens.[4]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
